Humira receives FDA approval for psoriasis

Biologic adalimumab (Humira, Abbott) has been approved by the FDA for a fifth indication—the treatment of moderate to severe chronic plaque psoriasis. The approval was based on results of two trials that showed marked improvement in skin condition. Almost three out of four patients achieved skin clearance of 75% or better and nearly half achieved 90% clearance. According to Abbott, one in five patients experienced complete clearance of psoriasis plaques. Adalimumab was previously approved for the treatment of ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and Crohn's disease.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, .